Hyloris annonce une date potentielle d’enregistrement pour Maxigesic® IV aux Etats-Unis
02 mai 2023 01h00 HE
|
Hyloris Pharmaceuticals SA
- La date limite d’enregistrement a été fixée au 17 octobre 2023 par la Food & Drug Administration des États-Unis. - Le partenaire commercial exclusif de Maxigesic® IV aux États-Unis est Hikma...
Hyloris announces potential registration date for Maxigesic® IV in the US
02 mai 2023 01h00 HE
|
Hyloris Pharmaceuticals SA
PDUFA goal date set for 17 October 2023 by U.S. Food & Drug AdministrationExclusive commercial partner for Maxigesic® IV in the U.S. is Hikma Pharmaceuticals, a leading supplier of complex,...
IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results
22 mars 2019 16h05 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter...
IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT®
20 nov. 2018 08h00 HE
|
IntelGenx Technologies Corp.
- PDUFA Goal Date of April 1, 2019 - SAINT LAURENT, Quebec, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that its...